SEARCH

SEARCH BY CITATION

References

  • Back, D. J. & J. F. Tjia: Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Brit. J. Clin. Pharmacol. 1991, 32, 624626.
  • Backman, J. T., C. Kyrklund, M. Neuvonen & P. J. Neuvonen: Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Therap. 2002, 72, 685691.
  • Baldwin, S. J., J. C. Bloomer, G. J. Smith, A. D. Ayrton, S. E. Clarke & R. J. Chenery: Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 1995, 25, 261270.
  • Baldwin, S. J., S. E. Clarke & R. J. Chenery: Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Brit. J. Clin. Pharmacol. 1999, 48, 424432.
  • Bidstrup, T. B., N. Stilling, P. Damkier, B. Scharling, M. S. Thomsen & K. Brøsen: Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. Eur. J. Clin. Pharmacol. 2004, 60, 109114.
  • Bourrié, M., V. Meunier, Y. Berger & G. Fabre: Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Therap. 1996, 277, 321332.
  • Eagling, V. A., J. F. Tjia & D. J. Back: Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Brit. J. Clin. Pharmacol. 1998, 45, 107114.
  • Eckland, D. A. & M. Danhof: Clinical pharmacokinetics of pioglitazone. Exp. Clin. Endocrinol. Diabetes 2000, 108 (suppl 2), 234242.
  • EMEA (European Medicines Agency): Actos. Annex I. Summary of product characteristics, Available from: URL: http:www. emea.eu.inthumandocsHumansEPARactosactos.htm. Accessed Jan 1, 2006.
  • FDA (Food and Drug Administration): Actos prescribing information, Available from: URL: www.fda.govcderfoilabel199921073lbl.pdf. Accessed Jan 1, 2006.
  • Hanefeld, M.: Pharmacokinetics and clinical efficacy of pioglitazone. Int. J. Clin. Pract. 2001, 121 (suppl), 1925.
  • Hruska, M. W., J. A. Amico, T. Y. Langaee, R. E. Ferrell, S. M. Fitzgerald & R. F. Frye: The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects. Brit. J. Clin. Pharmacol. 2005, 59, 7079.
  • Isoherranen, N., K. L. Kunze, K. E. Allen, W. L. Nelson & K. E. Thummel: Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab. Dispos. 2004, 32, 11211131.
  • Jaakkola, T., J. T. Backman, M. Neuvonen, J. Laitila & P. J. Neuvonen: Effect of rifampicin on the pharmacokinetics of pioglitazone. Brit. J. Clin. Pharmacol. 2006, 61, 7078.
  • Jaakkola, T., J. T. Backman, M. Neuvonen & P. J. Neuvonen: Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin. Pharmacol. Therap. 2005, 77, 404414.
  • Kajosaari, L. I., J. Laitila, P. J. Neuvonen & J. T. Backman: Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic & Clinical Pharmacology & Toxicology 2005, 97, 249256.
  • Ko, J. W., N. Sukhova, D. Thacker, P. Chen & D. A. Flockhart: Evaluation of omeprazole and lansoprazole as inhibitors ofcytochrome P450 isoforms. Drug Metab. Dispos. 1997, 25, 853862.
  • Lilja, J. J., J. T. Backman & P. J. Neuvonen: Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. Brit. J. Clin. Pharmacol. 2005, 59, 433439.
  • Lin, Z. J., W. Ji, D. Desai-Krieger & L. Shum: Simultaneous determination of pioglitazone and its two active metabolites in human plasma by LC-MS/MS. J. Pharm. Biomed. Anal. 2003, 33, 101108.
  • Newton, D. J., R. W. Wang & A. Y. Lu: Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos. 1995, 23, 154158.
  • Niemi, M., J. T. Backman, M. Granfors, J. Laitila, M. Neuvonen & P. J. Neuvonen: Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 2003a, 46, 13191323.
  • Niemi, M., J. T. Backman, M. Neuvonen & P. J. Neuvonen: Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 2003b, 46, 347351.
  • Niemi, M., J. T. Backman & P. J. Neuvonen: Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone. Clin. Pharmacol. Therap. 2004, 76, 239249.
  • Ogilvie, B. W., D. Zhang, W. Li, A. D. Rodrigues, A. E. Gipson, J. Holsapple, P. Toren & A. Parkinson: Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab. Dispos. 2006, 1, 191197.
  • Olkkola, K. T., J. T. Backman & P. J. Neuvonen: Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Therap. 1994, 55, 481485.
  • Ong, C. E., S. Coulter, D. J. Birkett, C. R. Bhasker & J. O. Miners: The xenobiotic inhibitor profile of cytochrome P4502C8. Brit. J. Clin. Pharmacol. 2000, 50, 573580.
  • Pelkonen, O., M. Turpeinen, J. Uusitalo, A. Rautio & H. Raunio: Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic & Clinical Pharmacology & Toxicology 2005, 96, 167175.
  • Richter, T., T. E. Mürdter, G. Heinkele, J. Pleiss, S. Tatzel, M. Schwab, M. Eichelbaum & U. M. Zanger: Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J. Pharmacol. Exp. Therap. 2004, 308, 189197.
  • Shitara, Y., M. Hirano, H. Sato & Y. Sugiyama: Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Therap. 2004, 311, 228236.
  • Turpeinen, M., A. Tolonen, J. Uusitalo, J. Jalonen, O. Pelkonen & K. Laine: Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation. Clin. Pharmacol. Therap. 2005, 77, 553559.
  • Walsky, R. L., E. A. Gaman & R. S. Obach: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J. Clin. Pharmacol. 2005a, 45, 6878.
  • Walsky, R. L., R. S. Obach, E. A. Gaman, J. P. Gleeson & W. R. Proctor: Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab. Dispos. 2005b, 33, 413418.
  • Wang, J.-S., M. Neuvonen, X. Wen, J. T. Backman & P. J. Neuvonen: Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab. Dispos. 2002, 30, 13521356.
  • Wang, J.-S., X. Wen, J. T. Backman, P. Taavitsainen, P. J. Neuvonen & K. T. Kivistö: Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacology & Toxicology 1999, 85, 157161.
  • Wen, X., J.-S. Wang, J. T. Backman, K. T. Kivistö & P. J. Neuvonen: Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab. Dispos. 2001, 29, 13591361.
  • Wen, X., J.-S. Wang, J. T. Backman, J. Laitila & P. J. Neuvonen: Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab. Dispos. 2002, 30, 631635.